Top Markets
Coin of the day
Petros Pharmaceuticals, Inc. Petros Pharmaceuticals, Inc.

Petros Pharmaceuticals, Inc.

PTPI
Rank in Stocks #40525
Petros Pharmaceuticals, Inc. is a pharmaceutical company dedicated to male... Petros Pharmaceuticals, Inc. is a pharmaceutical company dedicated to male health solutions. Their activities include both the commercialization and ongoing development of Stendra, a prescription PDE-5 inhibitor specifically designed for treating erectile dysfunction (ED). Furthermore, Petros is advancing H100, a proprietary topical formulation currently in development as a potential treatment for acute Peyronie's disease. The company's offerings also extend to a range of erectile dysfunction products, such as vacuum erection devices. Petros Pharmaceuticals, Inc. operates from its base in New York, New York.
Share Price
$0.0034
Market Cap
$144.07K
Change (1 day)
13.33%
Change (1 year)
-88.67%
Country
US
Trade Petros Pharmaceuticals, Inc. (PTPI)

Category

P/S ratio for Petros Pharmaceuticals, Inc. (PTPI)
P/S ratio as of 2026 TTM: 0
According to Petros Pharmaceuticals, Inc. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2026 the company had a P/S ratio of 0.
P/S ratio history for Petros Pharmaceuticals, Inc. from 2026 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
Not enough data for the provided dates.
P/S ratio for similar companies or competitors